Document is current

Article History

Received: 24 December 2023

Accepted: 23 January 2024

First Online: 23 February 2024

Conflict of interest

: D. Krug received remuneration from Merck Sharp & Dohme, med update, onkowissen, Astra Zeneca, Gilead, and Pfizer, as well as research support from Merck KGaA. M. Banys-Paluchowski received remuneration from Roche, Novartis, Pfizer, pfm, Eli Lilly, Onkowissen, Seagen, AstraZeneca, Eisai, Amgen, Samsung, Canon, MSD, GSK, Daiichi Sankyo, Gilead, Sirius Pintuition, Pierre Fabre, ExactSciences, Syantra, and Stemline, and study support from EndoMag, Mammotome, Merit Medical, Gilead, Hologic, ExactSciences, and Sirius Medical. S.Y. Brucker received remuneration from AstraZeneca, Roche, Novartis, Medtronic, Sanofi, Lilly, MSD, and Hologic. C. Denkert received remuneration from Novartis, Roche, MSD Oncology, Daiichi Sankyo, AstraZeneca, Merck, and Molecular Health, and study support from the European Commission, German Cancer Aid, BMBF, GBG, Myriad, and Roche; he is involved in patents for digital pathology (VMscope digital pathology software) and biomarker signatures (patents WO2015114146A1 and WO2010076322A1). N. Ditsch received remuneration from Gilead, MSD, Novartis, Pfizer, Roche, Seagen, AstraZeneca, Exact Sciences, Pierre-Fabre, I‑Med-Institute, Merit-Medical, pfm medical, Lilly, Aurikamed, Clinsol, and Onkowissen. P.A. Fasching received grants from Biontech, Pfizer, and Cepheid, and remuneration from Novartis, Pfizer, Daiichi Sankyo, Astra-Zeneca, Esai, Merck Sharp & Dohme, Lilly, Pierre Fabre, SeaGen, Roche, Agendia, Sanofi Aventis, Gilead, Mylan, and Menarini. N. Harbeck received remuneration from Amgen, Astra-Zeneca, Daiichi Sankyo, Gilead, Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Sandoz, Sanofi, Seagen, Viatris, and Zuelligpharma. J. Huober received research funding from Lilly, honoraria from Lilly, Novartis, Roche, Pfizer, AstraZeneca, Seagen, Gilead, and Daiichi, consulting fees from Lilly, Novartis, Roche, Pfizer, AstraZeneca, Gilead, and Daiichi, and travel expenses from Roche, Novartis, Daiichi, and Gilead. C. Jackisch received remuneration from Astra Zeneca, Lilly, Celgene, MSD, Eisai, Novartis, Pfizer, Gilead, Daiichi Sankyo, Medupdate, Streamed Up, and Roche, and research support from Exact Sciences. W. Janni received remuneration from AstraZeneca, Celgene, Chugai, Daiichi Sankyo, Eisai, ExactScience, GSK, Janssen, Lilly, Menarini, MSD, Novartis, Sanofi-Aventis, Roche, Pfizer, Seagen, Gilead, and Inivata. H.-C. Kolberg received remuneration from Pfizer, Novartis, Seagen, Roche, Genomic Health/Exact Sciences, Amgen, AstraZeneca, Riemser, Carl Zeiss Meditec, Teva, Theraclion, Janssen-Cilag, GSK, LIV Pharma, Lilly, SurgVision, Onkowissen, Gilead, Daiichi Sankyo, and MSD, as well as travel support from Carl Zeiss Meditec, LIV Pharma, Novartis, Amgen, Pfizer, Daiichi Sankyo, Tesaro, Gilead, and Menarini Stemline, and owns shares in Theraclion SA. S. Loibl did not receive any remuneration. The following companies granted support and remuneration to the GBG: Abbvie, Amgen, AZ, Celgene/BMS, Daiichi Sankyo, Gilead, GSK, Incyte, Lilly, MSD, Merck KG, Medupdate, Streamed Up, Novartis, Olema, Pfizer; Relay, Sanofi, Seagen, and Roche. D. Lüftner received remuneration from Amgen, Astra Zeneca, Celgene, Daiichi Sankyo, Eli Lilly, Gilead, GSK, high5md, Loreal, Novartis, onkowissen, Pfizer, Roche, and Teva. M. van Mackelenbergh received remuneration from Amgen, AstraZeneca, Daiichi Sankyo, GenomicHealth, Gilead, GSK, Lilly, Molecular Health, MSD, Mylan, Novartis, Pfizer, Pierre-Fabre, Roche, and Seagen, and travel fees from Daiichi Sankyo, Gilead, and Lilly. J.C. Radosa received remuneration from Pfizer, Eisai, MSD, Medac GmbH, Roche, Novartis, Gedeon Richter, Lilly, Pierre Fabre, Daiichi Sankyo, Seagen, and Theramex. T. Reimer received remuneration from AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, Myriad, Novartis, Pfizer, and Roche. M. Welslau received remuneration from Amgen, Astellas, AstraZeneca, Celgene, Gilead, Hexal, Janssen, Lilly, Novartis, Roche, and Sanofi, and has consulted and reviewed for Amgen, Bristol-Myers Squibb, Celgene, Gilead, Hexal, Janssen, Lilly, Medac, Novartis, Roche, Sanofi, and AstraZeneca. R. Würstlein received remuneration from Agendia, Amgen, Aristo, Astra Zeneca, Celgene, Clovis Oncology, Daiichi Sankyo, Eisai, Exact Sciences, Gilead, GlaxoSmithKline, Hexal, Lilly, Medstrom Medical, MSD, Mundipharma, Mylan, Nanostring, Novartis, Odonate, Paxman, Palleos, Pfizer, Pierre Fabre, PINK, PumaBiotechnology, Riemser, Roche, Sandoz/Hexal, Sanofi Genzyme, Seattle Genetics/Seagen, Stemline, Tesaro Bio, Teva, Veracyte, Viatris, FOMF, Aurikamed, Clinsol, Pomme Med, medconcept, and MCI. M. Untch: All remuneration to the employer (advisory boards and travel support): Amgen, AstraZeneca, Daiichi Sankyo, Eisai, Lilly, MSD Merck, Myriad Genetics, Pfizer, Roche, Pierre Fabre, Novartis, Seagen, Gilead, and Stemline. W. Budach received remuneration from Merck, BMS, Jörg Eickeler Veranstaltungen, and medpublico. R. Haidinger and J. Heil declare that they have no competing interests.